KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBITDA Margin (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EBITDA Margin for 9 consecutive years, with 60.2% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 8161.0% year-over-year to 60.2%, compared with a TTM value of 30.06% through Dec 2025, up 4987.0%, and an annual FY2025 reading of 30.06%, up 4987.0% over the prior year.
  • EBITDA Margin was 60.2% for Q4 2025 at Biocryst Pharmaceuticals, up from 7.78% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 60.2% in Q4 2025 and bottomed at 69.67% in Q4 2023.
  • Average EBITDA Margin over 3 years is 8.95%, with a median of 10.5% recorded in 2024.
  • Peak annual rise in EBITDA Margin hit 8161bps in 2025, while the deepest fall reached 1522bps in 2025.
  • Year by year, EBITDA Margin stood at 69.67% in 2023, then skyrocketed by 69bps to 21.41% in 2024, then surged by 381bps to 60.2% in 2025.
  • Business Quant data shows EBITDA Margin for BCRX at 60.2% in Q4 2025, 7.78% in Q3 2025, and 3.43% in Q2 2025.